PRESS RELEASES

Date	Title
Jul 29, 2021	Ardelyx Receives Complete Response Letter from U.S. FDA for New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
Jul 19, 2021	Ardelyx Provides Regulatory Update on New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
Jun 7, 2021	Ardelyx Announces Presentations at ERA-EDTA Virtual Congress 2021
May 25, 2021	Ardelyx to Present at the Jefferies 2021 Virtual Healthcare Conference
May 6, 2021	Ardelyx Reports First Quarter 2021 Financial Results and Recent Business Highlights
Apr 29, 2021	Ardelyx Announces Extension of the PDUFA Review Period for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
Apr 16, 2021	Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 14, 2021	Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initiation of Phase 3 Clinical Studies of Tenapanor for Hyperphosphatemia in Japan
Apr 12, 2021	Ardelyx Announces Upcoming Data Presentation at ISN World Congress of Nephrology 2021
Mar 30, 2021	Ardelyx Announces Poster Presentations, Educational Symposium, and Exhibitor Showcase at National Kidney Foundation 2021 Virtual Spring Clinical Meetings

FAQs

Email Alerts

Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Boston Area
200 West Street, 4th Floor
Waltham, MA 02451

Phone: 510.745.1700

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com